NAD+ Recharge Revives Aging CAR-T Cells and Could Transform Cancer Immunotherapy

CAR-T cell therapy has transformed oncology, yet elderly cancer patients consistently experience inferior outcomes compared to younger individuals. A growing body of evidence implicates age-related immune dysfunction—immunosenescence—as a central culprit, but the precise metabolic mechanisms have remained poorly understood. This commentary, authored by Fan, Wang, and Wang in Trends in Cancer (2025), discusses a landmark study by Hope et al. published in Nature Cancer that directly links declining intracellular NAD+ levels to CAR-T cell failure in aged donors.

NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme involved in cellular energy metabolism, mitochondrial function, and multiple signaling pathways including sirtuins and PARP enzymes. As organisms age, NAD+ levels decline significantly across tissues, including in immune cells. Hope et al. demonstrated that this decline is not merely a bystander effect of aging but a causative driver of metabolic dysfunction in T cells—compromising their proliferative capacity, effector function, and overall fitness needed for effective anti-tumor activity.

The key result highlighted in this commentary is that pharmacologically restoring NAD+ levels—using NAD+ precursors or related interventions—can reverse these age-associated deficits in CAR-T cells. Rejuvenated T cells showed improved metabolic fitness, reduced markers of senescence, and enhanced anti-tumor efficacy. This establishes a mechanistic and therapeutic proof-of-concept linking NAD+ metabolism directly to immunotherapy outcomes in the context of aging.

The implications are substantial. The authors coin the term 'Metabolic-Immunotherapy' to describe this combined approach: optimizing cellular metabolic state as a prerequisite or adjunct to immunotherapy. Because NAD+ decline is a universal hallmark of aging rather than disease-specific, this strategy could benefit elderly patients with diverse cancer types undergoing CAR-T or potentially other T-cell-based therapies. Clinically available NAD+ precursors such as NMN and NR are already in use for other indications, potentially accelerating translation.

However, several caveats warrant consideration. The commentary is a perspective piece and does not itself present new primary data—the strength of the conclusions depends entirely on the Hope et al. study. The translation from preclinical or ex vivo findings to clinical benefit in elderly cancer patients requires rigorous prospective trials. Additionally, the optimal NAD+ restoration strategy, dosing, timing relative to CAR-T infusion, and long-term safety in immunocompromised oncology patients remain to be defined.